Your Search Results

TAVI in heart failure is possible

21 May 2026 – From EuroPCR 2026

This session demonstrates the feasibility of transcatheter aortic valve implantation (TAVI) in patients with heart failure through a series of challenging cases. It covers sequential management of hypertrophic obstructive cardiomyopathy with aortic stenosis, advanced heart failure interventions, staged approaches in cardiogenic shock, and complex percutaneous interventions...

Refining the gold standard: what is new in DES

21 May 2026 – From EuroPCR 2026

This session explores recent advancements in drug-eluting stent (DES) technology, featuring global real-world evidence on short dual antiplatelet therapy (DAPT) with polymer-free DES, angiographic outcomes from pooled TARGET trials, and real-world registry data on various DES platforms. It also presents post-marketing surveillance results and systematic reviews...

Calcified lesion of distal protected left main - LIVE case

22 May 2026 – From EuroPCR 2026

An 85‑year‑old man with type 2 diabetes mellitus, hypertension, dyslipidemia, peripheral artery disease, COPD, and chronic kidney disease presented with CCS class II angina related to three‑vessel coronary artery disease. He had previously undergone hybrid revascularization, including PCI of the RCA ostium and CABG with LIMA...

Calcified lesion of distal protected left main - LIVE case

Diagnosis and management of INOCA and ANOCA

21 May 2026 – From EuroPCR 2026

This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

18 Sep 2022

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Author

Jonathan Curio

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

Outcomes in patients with atrial fibrillation randomized to receive LAA closure or oral anticoagulation: Primary results of the CHAMPION-AF clinical trial

28 Mar 2026

During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).